Valeant | pharmaphorum

Skip to main content

Sunday 20 April 2025

twitter linkedin facebook rss

User account menu

Subscribe

Channels

Content type

Categories

Categories

Sort by

Order

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

Valeant

News

Valeantlogo

Valeant/Philidor execs convicted of multimillion dollar frau...

A duo of former executives from beleaguered drug maker Valeant and its defunct mail order pharmacy Philidor have been found guilty of a multimillion dollar fraud – and the f

News

Valeantlogo

Valeant sells female libido drug back to former owners

Valeant has sold its controversial female libido drug to former shareholders in Sprout, the company that first developed it before a $1 billion buyout two years ago.

News

eye

FDA approves Valeant eye drug after manufacturing delay

Regulator backs potential blockbuster ophthalmology drug

News

J&J

J&J's psoriasis drug faces crowded market after US approval

J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.

News

Shire HQ

Shire plans filing for HAE drug after phase 3 success

Lanadelumab could revolutionise treatment of swelling disease.

News

Valeantlogo

Valeant's Siliq price undercuts rivals to offset black box w...

Siliq will be cheaper than rivals from Novartis and Eli Lilly.

Load more results

Editor's Picks

Trump pledges drug price cuts – and action on 'pill penalty'

Lilly soars on first data for oral obesity candidate

Norgine on a growth charge again with Theravia takeover deal

FDA clears first migraine DTx from Click Therapeutics

After delay, Alzheimer's drug Leqembi gets green light in EU

Market Access

New FDA head says no more pharma on advisory committees

New FDA head says no more pharma on advisory committees

The announcement signals a new administration attempting to distance itself from industry, but the actual impact seems small.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Abstract visual of head

Sponsored

Health Trends 2025: Reimagining What's Possible

Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Subscribe

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company